Khan Hina, Zamir Ammara, Imran Imran, Saeed Hamid, Alqahtani Faleh, Majeed Abdul, Aziz Majid, Rasool Muhammad Fawad
Department of Pharmacy Practice, Bahauddin Zakariya University, Multan, Pakistan.
Department of Pharmacology, Bahauddin Zakariya University, Multan, Pakistan.
Expert Opin Drug Metab Toxicol. 2025 Jan;21(1):69-79. doi: 10.1080/17425255.2024.2402478. Epub 2024 Sep 12.
Glipizide is an oral antidiabetic drug widely used to treat non-insulin-dependent type II diabetes mellitus (NIDDM). This systematic review extensively examines all reported pharmacokinetic (PK) parameters of glipizide in healthy and diseased populations.
A total of 31 articles were retrieved after screening various databases, i.e. Google Scholar, PubMed, Science Direct, and Cochrane, regarding the PK parameters of glipizide in healthy, diseased, drug-drug, and drug-food interaction studies. The C was 35% higher in healthy Koreans than in Caucasian Americans. In type II diabetes patients, the AUC increases ~2-fold after multiple dosage regimen in comparison with a single dose. Furthermore, the C increased in fasting conditions compared to the non-fasting state in diabetic individuals i.e. 1338.28 ± 125.18 ng/mL and 1297.29 ± 47.22 ng/mL, respectively.
The presented data has depicted that glipizide exposure varies between single and multiple dosing and its C also changes between different demographic populations. Since it has a shorter half-life, the development of its new extended-release formulations may assist practitioners in improving adherence among diabetic patients.
CRD42024538428.
格列吡嗪是一种口服抗糖尿病药物，广泛用于治疗非胰岛素依赖型II型糖尿病（NIDDM）。本系统评价广泛研究了格列吡嗪在健康人群和患病群体中所有已报道的药代动力学（PK）参数。
在筛选了各种数据库（即谷歌学术、PubMed、科学Direct和Cochrane）中有关格列吡嗪在健康、患病、药物-药物和药物-食物相互作用研究中的PK参数后，共检索到31篇文章。健康韩国人的C比美国白种人高35%。在II型糖尿病患者中，多次给药方案后的AUC比单次给药增加约2倍。此外，糖尿病个体在禁食条件下的C比非禁食状态下有所增加，分别为1338.28±125.18 ng/mL和1297.29±47.22 ng/mL。
所呈现的数据表明，格列吡嗪的暴露量在单次和多次给药之间有所不同，其C在不同人群中也会发生变化。由于其半衰期较短，开发新的缓释制剂可能有助于医生提高糖尿病患者的依从性。
PROSPERO注册号：CRD42024538428。
